by
Duncan E Berry;
Clay J Bavinger;
Alcides Filho Fernandes;
John Mattia;
Jalika Mustapha;
Lloyd Harrison-Williams;
Moges Teshome;
Matthew J Vandy;
Jessica Shantha;
Steven Yeh
The largest Ebola virus disease (EVD) outbreak occurred from 2013–2016 in West Africa, leading to over 28,600 cases and 11,300 deaths and resulted in the largest cohort of EVD survivors to date.1 Another recent outbreak in Democratic Republic of the Congo (DRC) has resulted in 3,481 cases with over 1,170 survivors since August 2018.2 In studies of large EVD survivor cohorts, uveitis is the most common ocular manifestation with a 13–34% reported prevalence.3,4 Cataract, with or without uveitis, is the second most common finding and has been reported in 10% of EVD survivors.3,4 The Ebola Virus Persistence in Ocular Tissues (EVICT) study was a cross-sectional study which supported the safety of cataract surgery in EVD survivors5, but may not be generalizable to vitreoretinal surgery. Posterior segment findings in EVD survivors have been described primarily in relationship to uveitis and include vitritis, chorioretinitis and chorioretinal scarring.3,6 The prevalence of posterior segment findings in EVD survivors, particularly those that may require surgical intervention, is of particular interest given the risk of Ebola virus (EBOV) persistence in ocular tissues and fluids.7